Skip to main content
Welcome to
Sanofi
About us
About us
U.S. LEADERSHIP
Our Stories
Corporate Compliance
Corporate Compliance
California Compliance Law
Shannon Kelley
California Compliance Law - Sanofi Pasteur
Compliance Program for Sanofi Pasteur
Committed to Transparency
Sanofi Websites in the U.S.
Your Health
Your Health
Vaccines
Science & Innovation
Science & Innovation
Clinical Trials
INVESTIGATOR SPONSORED STUDIES (ISS)
Products & Resources
Products & Resources
Prescription Products
Vaccines Products
Vaccines Products
Yellow Fever Vaccine Information
Generics
Consumer Health (OTC) Products
U.S. Patents
Patient Support Services
Resources for Healthcare Providers
Colorado Disclosure
Vermont Disclosure
Our Responsibility
Our Responsibility
Corporate Social Responsibility
Access to Healthcare
Patient Advocacy at Sanofi in the U.S.
Patient Advocacy at Sanofi in the U.S.
Health Equity at Sanofi in the U.S.
2023 Health Equity Accelerator Awards: Application Guidelines
2022 Health Equity Accelerator Award Winners
Health Equity Accelerator Awards Aim to Expand Solutions for Bigger Impact
Patient Centered Healthcare Value Assessment
Diversity, Equity & Inclusion
Diversity, Equity & Inclusion
A Million Conversations: Addressing Disparities in Healthcare
Diversity in Clinical Trials
Employee Resource Groups
Supplier Diversity
Contributions and Giving
Contributions and Giving
TORCH Awards
Sponsorships
Philanthropic Donations
Healthcare Contributions
Independent Medical Education (IME/CME) Grants
Fellowships
Rare Genetic Disease Fellowships
Patient Assistance Foundations
Pricing Principles
Pricing Principles
2023 Pricing Principles Report
Clear Rationale for Pricing
Limited U.S. Price Increases
Continued Transparency in the U.S.
Prioritizing Patient Affordability
Healthy Planet
Careers
Careers
Benefits
Diversity
Postdoctoral Careers
Physician Careers
Students
Veterans
Investors
Media
Toggle navigation
Home
Press Releases
Subscribe
Social Media
Media Contacts
Press Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
Keywords
Go
Advanced Search
Search
Search Headlines Only
Category
All Categories
Corporate News
Product News
Provention Bio archive
Vaccines News
Uncategorized
From
To
Asset Types
Video
Audio
Photos
Documents
Events
Standard
Jun 29, 2022
Sanofi to lower out-of-pocket cost of insulin for uninsured patients and expand access in underserved communities
Through the Insulins Valyou Savings Program, uninsured people living with diabetes will pay fixed $35 for a 30-day supply of Sanofi insulins
Jun 22, 2022
Sanofi Statement on ACIP 2022-2023 Influenza Recommendations for People 65+
Jun 22, 2022
Survey: Physicians and pharmacists would tell CDC to recommend vaccine like Fluzone High-Dose Quadrivalent (Influenza Vaccine) for people 65 years and older
Results of nationally representative survey come as the ACIP evaluates data to provide guidance for flu vaccines in this vulnerable population
Jun 7, 2022
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Jun 7, 2022
Sanofi unveils new 900,000-square-foot campus at Cambridge Crossing
Jun 3, 2022
Provention Bio Announces the Grant of Inducement Awards
Jun 3, 2022
Provention Bio to Present at the Jefferies Global Healthcare Conference
Jun 3, 2022
Provention Bio Announces Update to Board of Directors
Jun 2, 2022
Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab-rwlc)
Sanofi will receive an upfront payment of $900 million, and an 11% royalty on worldwide net sales of Libtayo
Jun 1, 2022
FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A
Efanesoctocog alfa is the first factor VIII therapy to be awarded Breakthrough Therapy designation by the FDA
Show
5
10
25
50
100
per page
«
1
…
6
7
8
9
10
11
12
…
112
»
Print
Email page
RSS